REPORTING OF CARDIOVASCULAR RISK FACTORS IN LANDMARK IMMUNE CHECKPOINT INHIBITOR TRIALS

被引：0
|
作者：
Tan, Sean
Sivakumar, Seiyon
Segelov, Eva
Nicholls, Stephen J.
Nelson, Adam J.
机构：
[1] Victorian Heart Inst, Melbourne, Vic, Australia
[2] Monash Heart, Melbourne, Vic, Australia
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1154-007
引用
收藏
页码：2168 / 2168
页数：1
相关论文
共 50 条
  • [41] CHARACTERIZATION OF CARDIOVASCULAR EVENTS IN IMMUNE CHECKPOINT INHIBITOR INDUCED MYOCARDITIS
    Pereyra, Milagros
    Farina, Juan
    Roarke, Michael
    Mahmoud, Ahmed K.
    Scalia, Isabel G.
    Masson, Rajeev
    Wasef, Beman
    Tagle-Cornell, M. Cecilia A.
    Kenyon, Courtney
    Said, Ebram
    O'Shea, Michael P.
    Barry, Timothy
    Narayanasamy, Hemalatha
    Ray, Jordan Christopher
    El Masry, Hicham Z.
    Larsen, Carolyn
    Herrmann, Joerg
    Arsanjani, Reza
    Ayoub, Chadi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2565 - 2565
  • [42] Immune checkpoint inhibitor-associated cardiovascular toxicities: A review
    Liu, Guihong
    Chen, Tao
    Zhang, Xin
    Hu, Binbin
    Shi, Huashan
    HELIYON, 2024, 10 (05)
  • [43] Arthritis risk with immune checkpoint inhibitor therapy for cancer
    Pundole, Xerxes
    Abdel-Wahab, Noha
    Suarez-Almazor, Maria E.
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 293 - 299
  • [44] Immune checkpoint inhibitors: Unravelling atherosclerotic cardiovascular risk
    Gray, Rhys
    Manisty, Charlotte
    Cheng, Richard
    Dastidar, Amardeep
    Mamas, Mamas
    Ghosh, Arjun
    ATHEROSCLEROSIS, 2025, 403
  • [45] Immune checkpoint inhibitors: risk of severe cardiovascular events
    Reactions Weekly, 2018, 1729 (1) : 7 - 7
  • [46] Cardiotoxicity risk factors with immune checkpoint inhibitors
    Zachary L. Brumberger
    Mary E. Branch
    Max W Klein
    Austin Seals
    Michael D. Shapiro
    Sujethra Vasu
    Cardio-Oncology, 8
  • [47] Cardiotoxicity risk factors with immune checkpoint inhibitors
    Brumberger, Zachary L.
    Branch, Mary E.
    Klein, Max W.
    Seals, Austin
    Shapiro, Michael D.
    Vasu, Sujethra
    CARDIO-ONCOLOGY, 2022, 8 (01)
  • [48] Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity
    Cluxton, Christopher
    Naidoo, Jarushka
    CURRENT ONCOLOGY, 2023, 30 (07) : 6862 - 6871
  • [49] Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC
    Yoo, S. H.
    Kim, M.
    Keam, B.
    Kim, T. M.
    Kim, D-W.
    Heo, D. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review
    Schonfeld, Ethan
    Choi, John
    Tran, Andrew
    Kim, Lily H.
    Lim, Michael
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
12345